1497 results about "Cross reactions" patented technology

The invention discloses a liquid phase chip for CYP19A1 gene SNP (Single Nucleotide Polymorphism) detection, which comprises wild type and mutant type specific ASPE primers designed targeting CYP19A1 gene SNPs of rs4646, rs10046C>T, rs700519C>T, rs1870050C>A, hCV1664178A>C, rs12900137G>C, rs730154G>A, rs936306T>C and rs1902586A>G, microballoon spheres respectively coated with specific anti-tag sequences and primers used for amplifying CYP19A1 gene SNPs with target sequences to be detected. Each ASPE primer comprises a tag sequence at 5' end and a specific primer sequence at 3' end, wherein the specific primers are selected from SEQ ID NO. 19-36 and the tag sequences are selected from SEQ ID NO.1-18; and the anti-tag sequences can be correspondingly in complementary pairing with the tag sequences. The invention also discloses a CYP19A1 gene SNP detection method. The coincidence rate of the detection method provided by the invention and a sequencing method is as high as 100%; and the prepared liquid phase chip for CYP19A1 gene SNP (Single Nucleotide Polymorphism) detection has excellent signal-to-noise rate, and basically no cross reaction exists between a design probe and the anti-tag sequences.

The invention discloses a CYP3A4 gene SNP detection specific primer, a liquid-phase chip and a method; and the liquid-phase chip comprises wild-type and mutant ASPE primers which are respectively designed for each type of mutation points, microspheres which are respectively coated with specific anti-tag sequences, and the primer which is used for amplifying a CYP3A4 gene target sequence with CYP3A4*1B, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*6, CYP3A4*15, CYP3A4*17, CYP3A4*18 and/or CYP3A4*19SNP sites. The CYP3A4 gene SNP detection liquid-phase chip has very good signal-noise ratio, and a designed probe and the anti-tag sequences essentially have no cross reaction. The designed ASPE primers have very good specificity and can accurately distinguish all types of mutation points. The detection method has simple steps and ten types of SNP sites can be detected at one step, so that the operation is convenient, thereby preventing a plurality of uncertain factors in a plurality of operation processes, and greatly improving the detection accuracy rate.

The invention discloses a carbamazepine immunogen, a carbamazepine specific antibody directly obtained through the immunogen, a detection reagent containing the specific antibody and a method for detecting the content of the carbamazepine in samples to be tested. The immunodetection reagent and the detection method have the advantages that the carbamazepine immunogen is strong in specificity and high in immunogenicity; the prepared carbamazepine immunogen is strong in specificity and high in titer and has no cross reaction with 45 common drugs; the homogeneous enzyme immunodetection reagent containing the carbamazepine specific antibody can conveniently, fast and accurately determine the content of the carbamazepine in the samples and can measure a plurality of samples simultaneously on a full-automatic biochemical analyzer, so that high-throughput and fast measuring of the carbamazepine are achieved, the accuracy is high, the specificity is strong, the accuracy and the detection efficiency are greatly improved compared with the prior art, full automation in the detection process is achieved simultaneously, the requirements on detection staff is not high, and the immunodetection reagent and the detection method are easy to achieve, popularize and use.

The present invention relates to a hybridoma cell line 3G1 and an anti-alfatoxin B1 monoclonal antibody produced by the hybridoma cell line 3G1. The hybridoma cell line 3G1 (CCTCCNO.C201014) can be used for preparation of a high titer anti-aflatoxin B1 monoclonal antibody, wherein an enzyme-linked immunosorbent assay (ELISA) method is adopted to determine a titer, and the titer is 6.40*10<6>. The anti-aflatoxin B1 monoclonal antibody of the present invention has characteristics of high sensitivity and good specificity, wherein 50% inhibiting concentration on aflatoxin B1 by the monoclonal antibody is 1.6 ng/mL, cross reaction rate with aflatoxin B2 is 6.4%, and cross reaction rates with aflatoxin G1 and G2 are less than 1%. In addition, the anti-aflatoxin B1 monoclonal antibody of the present invention can be used for determination of aflatoxin B1.

The invention relates to a respiratory tract common pathogen multiple PT-PCR combined gene chip detection kit. The kit detects one or more of 22 respiratory tract common pathogens by the usage of multiple specific conservative degenerate primer combination and probe combination and provided with endogenous control, positive control and negative control at the same time. According to the detection kit, the coverage rate for a high mutant pathogen subject sequence is increased, the problem of nonspecific cross reaction between the multiple primers and the probe is avoided, one single reaction system can detect more than 20 respiratory tract common pathogens simultaneously, and a detection tool which is simple and sensitive, rapid and large in flux and capable of carrying out multi-index parallel detection is provided for respiratory tract common pathogen detection.

The invention discloses a method for detecting an allergen almond component in foods by a fluorescent PCR technology, belonging to allergen detecting technologies, in particular a method for detectingan allergen almond component in foods by an exonuclease probe fluorescent PCR technology (TaqMan). Aiming at an allergen almond component Pru du 1.06B DNA sequence a primer and a TaqMan probe are designed, the fluorescent PCR detecting method is established. The method includes the designed primer and a probe of the almond component specificity, and the fluorescent PCR reaction condition matchedwith the primer and the probe. The method has no cross reaction with peanuts, hazelnuts, chestnuts, walnuts, pine nuts, macadamia nuts, and the like and has specificity; and the detecting sensitivitycan reach 5mg/kg. The method can be used for detecting the allergen in the foods and preventing anaphylactic reaction caused by the foods and has practical meanings.

The invention discloses molecularly imprinted polymers (MIPs) for detecting melamine and a preparation method thereof. The MIPs are prepared by the steps as follows: cyromazine is used as a virtual moulding board and is polymerized with a functional monomer, a cross linker agent, a pore-foaming agent and an initiator at the temperature from 50 to 80 DEG C to obtain a bulk polymer; and after being processed by the operations of pulverization, screen separation, moulding board removal by acetic acid methanol and methanol, the bulk polymer is processed by vacuum drying to prepare the MIPs which have high cross reaction and outstanding selectivity to melamine. The invention selects the cyromazine as the virtual moulding board to prepare the MIPs, and avoids the problem that the melamine is hard to dissolve in a polymerization system and the problem that when the MIPs prepared by using the melamine as the moulding board is used for solid phase extraction of fill materials, moulding board leakage can lead to an inaccurate result; the invention selects the mixed system of methanol and water as the pore-foaming agent, and the prepared MIPs have high compatibility with the melamine in an aqueous solution; and used as a sample pre-processing material for analyzing the melamine, the prepared MIPs have broad application prospect.

Novel bactericidal antibodies against Neisseria meningitidis serogroup B (“MenB”) are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are used to identify molecular mimetics of unique epitopes found on MenB or E. coli K1. Examples of such peptide mimetics are described that elicit serum antibody capable of activating complement-mediated bacteriolysis of MenB. Vaccine compositions containing such mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody.

The present invention comprises methods and compositions for producing and/or enhancing an immunological response in a subject against a target moiety such as a disease-related moiety by administration of an antigenic version of the target moiety having one or more unnatural amino acid and/or by administration of an antibody against a version of a target moiety having one or more unnatural amino acid which antibody is cross reactive with the natural target moiety.

The invention discloses a fluorescent microsphere lateral chromatographic detection strip for multiple joint inspection of trace target substances as well as a preparation method and application thereof. The fluorescent microsphere lateral chromatographic detection strip is characterized by comprising a soleplate, wherein the top of the soleplate is sequentially provided with a sample absorption pad, a combination pad, a chromatographic film and a piece of water absorption paper from left end to right end, the right end of the sample absorption pad is pressed to be attached onto the left end of the combination pad, the right end of the combination pad is pressed to be attached onto the left end of the chromatographic film, the left end of the water absorption paper is pressed to be attached onto the right end of the chromatographic film to form a lateral chromatographic detection structure; the chromatographic film is provided with a detection line and a quality control line from left to right; the combination pad is formed by a polyester fiber film and fluorescent microspheres marked with different ligands on the polyester fiber film, and the chromatographic film consists of a nitrocellulose film and a plurality of detection lines which are arranged on the nitrocellulose film and contain different ligands which can be specifically combined with the target substances. The fluorescent microsphere lateral chromatographic detection strip can be used for performing multiple joint inspection on a plurality of trace target substances simultaneously, all display results have no cross reaction and are dependent from one another, the detection sensitivity and accuracy can be remarkably improved, rapidness and convenience in operation can be realized, and an important significance on biological detection and early diagnosis and treatment of diseases can be achieved.

The invention provides an amphimorphic FQ-PCR detection reagent kit for identifying African swine fever and swine fever virus wild strains. A P72 gene of ASFV and a 5'UTR noncoding region of CSFV arerespectively used as an amplification target area, a pair of specific primers and a TaqMan MGB probe (SEQ ID NO:1-6) are designed, a real-time fluorescent quantitation PCR(FQ-PCR) technique is used, and identification and detection of ASFV and CSFV are realized. The detection reagent kit provided by the invention is suitable for detecting viral nucleic acid in samples of serum, spleen, lymph nodes, tonsil, kidney and the like of suspected ASFV or CSFV infected pigs, the sensitivity can reach 1.0*10<1>copy/[mu]L, and the detection reagent kit does not have any cross reactions with other pathogens which are liable to be in mixed infection with the ASFV and the CSFV or of which the infection symptoms are similar such as PRRSV, PRV, PCV2, PPV, JEV and HPS.

The invention provides an immunity diagnosis test kit for detecting II-type dengue virus antigen, which comprises a porous reaction plate covering monoclonal antibody DV2-M6, a sample treatment liquid, a monoclonal antibody DV2-M15 marked with a label, a positive contrast, a negative contrast, a concentration washing liquid, a develop liquid and a termination liquid, wherein the monoclonal antibodies DV2-M6 and DV2-M14 of the test kit can be specifically combined with NS1 protein of II-type dengue virus, without cross reaction with other three kinds of serotype dengue viruses NS1 and respectively combined with different antigen points of NS1, while the check sensitivity of NS1 protein of II-type dengue virus can reach 3ng/ml and the check sensitivity of culture supernatant of II-type dengue virus infection cell is 8 power of Pan-E dengue early elisa test kit, thereby improving the sensitivity of clinical serum sample check.

A method for the prediction of adverse cross-reactions between lead candidate biomolecules and potential reactant molecules, often biopolymers, is described. In a computational system, reactions are modeled within a suitable environment, in order to determine a reaction profile between a lead candidate molecule and a potential reactant molecule. A risk assessment is then generated for each lead based on a plurality of reaction profiles for the lead with respect to a plurality of potential reactant molecules. The method includes provisions for redesign and optimization of the lead candidate, possibly iterative in nature, in order to avoid predicted adverse cross-reactions.

The invention discloses a blocking ELISA kit for detecting an NDV (Newcastle disease virus) antibody. The blocking ELISA kit for detecting the NDV antibody comprises an ELISA plate coated with an NDV inactivated antigen, an NDV positive control serum, an NDV negative control serum and a horseradish peroxidase labeled NDV NP protein monoclonal antibody, wherein the horseradish peroxidase labeled NDV NP protein monoclonal antibody is secreted by a hybridoma cell strain with the preservation number being CCTCC NO: C2016180. The blocking ELISA kit for detecting the NDV antibody can detect serum samples which are infected with the suspected NDV and are from different species, can distinguish an MG7-deficient vaccine from an NDV serum after being infected with a wild virus, and has no cross reaction with a common avian viral pathogen positive serum, thereby being high in sensitivity and specificity, good in reproducibility and suitable for high-throughput detection of serum samples.

This invention relates to agents that bind multiple Siglecs, including antibodies that neutralize the inhibitory activity of multiple Siglec-7 and Siglec-9 in lymphocytes. Such agents can be used for the treatment of cancers or infectious disease.

The invention belongs to the field of biomedicine, and provides a method for determining a cross antigen region initiating human antigens in human enterovirus 71-type (EV71) total protein. In the method, the human enterovirus 71-type total protein is identified through segmental expression; and cross reaction between immunogenic and inductive antibodies and the human antigens in each segment is performed, and different segments of the human enterovirus 71-type total protein are divided into three classes: (1) strongly-crossed immunogens initiating the human antigens; (2) weakly-crossed immunogens initiating the human antigens; and (3) no crossed immunogens existing between the antibodies and the human antigens. Thus, the method plays a guidance role in developing and preparing human enterovirus 71-type vaccines, and hand-foot-and-mouth disease vaccines having no cross reaction or weak cross reaction with human bodies can be designed according to the method.

The invention discloses a lipoprotein (a) detection kit which is characterized by consisting of a reagent 1, a reagent 2 and a working calibration solution. The reagent 1 consists of a buffer solution, bull serum albumin (BSA), a surfactant, goat IgG and NaN3; the reagent 2 consists of a buffer solution, a lipoprotein (a) monoclonal antibody latex microsphere, BSA, the surfactant, the goat IgG, a stabilizer and NaN3. The lipoprotein (a) detection kit can be applied to a fully automatic biochemical analyzer, the detection result is high in accuracy, and the lipoprotein (a) has high comparability with absolute concentration of lipoprotein (a) of different crowds and different sizes. Moreover, the lipoprotein (a) detection kit does not have a cross reaction with plasminogen, is not interfered by rheumatoid factors and is high in reagent stability, convenient to use and convenient for large-scale popularization, only a monoclonal antibody of the lipoprotein (a) is needed, and the preparation cost and time of the kit are saved.

The invention discloses a hapten and complete antigen used for ketamine detection and antibody preparation. The invention also discloses an anti-ketamine monoclonal antibody prepared by the complete antigen and a colloidal gold-labeled ketamine monoclonal antibody immunoassay plate used for detecting ketamine in drugs or urine, etc., human samples. Compared with HPLC method, the invented detection plate is simple, portable and easy to carry, and can be used for spot detection without need of expensive equipment. The whole detection for ketamine by using the detection plate can be completed in 10 minutes with sensitivity up to 50 ng and with no cross reaction with 39 kinds of common pharmaceuticals, drugs, and ketamine metabolites in vivo.